Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 201

1.

The Mitochondrial Targets of Neuroprotective Drug Vinpocetine on Primary Neuron Cultures, Brain Capillary Endothelial Cells, Synaptosomes, and Brain Mitochondria.

Svab G, Doczi J, Gerencser AA, Ambrus A, Gallyas F, Sümegi B, Tretter L.

Neurochem Res. 2019 Oct;44(10):2435-2447. doi: 10.1007/s11064-019-02871-9. Epub 2019 Sep 18.

2.

PARP Inhibitor PJ34 Protects Mitochondria and Induces DNA-Damage Mediated Apoptosis in Combination With Cisplatin or Temozolomide in B16F10 Melanoma Cells.

Cseh AM, Fabian Z, Quintana-Cabrera R, Szabo A, Eros K, Soriano ME, Gallyas F, Scorrano L, Sumegi B.

Front Physiol. 2019 May 7;10:538. doi: 10.3389/fphys.2019.00538. eCollection 2019.

3.

PARP Inhibitor Protects Against Chronic Hypoxia/Reoxygenation-Induced Retinal Injury by Regulation of MAPKs, HIF1α, Nrf2, and NFκB.

Kovacs K, Vaczy A, Fekete K, Kovari P, Atlasz T, Reglodi D, Gabriel R, Gallyas F, Sumegi B.

Invest Ophthalmol Vis Sci. 2019 Apr 1;60(5):1478-1490. doi: 10.1167/iovs.18-25936.

PMID:
30973576
4.

PARP inhibition induces Akt-mediated cytoprotective effects through the formation of a mitochondria-targeted phospho-ATM-NEMO-Akt-mTOR signalosome.

Tapodi A, Bognar Z, Szabo C, Gallyas F, Sumegi B, Hocsak E.

Biochem Pharmacol. 2019 Apr;162:98-108. doi: 10.1016/j.bcp.2018.10.005. Epub 2018 Oct 6.

5.

Orthologous proteins of experimental de- and remyelination are differentially regulated in the CSF proteome of multiple sclerosis subtypes.

Martin NA, Nawrocki A, Molnar V, Elkjaer ML, Thygesen EK, Palkovits M, Acs P, Sejbaek T, Nielsen HH, Hegedus Z, Sellebjerg F, Molnar T, Barbosa EGV, Alcaraz N, Gallyas F Jr, Svenningsen AF, Baumbach J, Lassmann H, Larsen MR, Illes Z.

PLoS One. 2018 Aug 16;13(8):e0202530. doi: 10.1371/journal.pone.0202530. eCollection 2018.

6.

Experimental Demyelination and Axonal Loss Are Reduced in MicroRNA-146a Deficient Mice.

Martin NA, Molnar V, Szilagyi GT, Elkjaer ML, Nawrocki A, Okarmus J, Wlodarczyk A, Thygesen EK, Palkovits M, Gallyas F Jr, Larsen MR, Lassmann H, Benedikz E, Owens T, Svenningsen AF, Illes Z.

Front Immunol. 2018 Mar 12;9:490. doi: 10.3389/fimmu.2018.00490. eCollection 2018.

7.

Activation of mitochondrial fusion provides a new treatment for mitochondria-related diseases.

Szabo A, Sumegi K, Fekete K, Hocsak E, Debreceni B, Setalo G Jr, Kovacs K, Deres L, Kengyel A, Kovacs D, Mandl J, Nyitrai M, Febbraio MA, Gallyas F Jr, Sumegi B.

Biochem Pharmacol. 2018 Apr;150:86-96. doi: 10.1016/j.bcp.2018.01.038. Epub 2018 Feb 3.

8.

Desethylamiodarone-A metabolite of amiodarone-Induces apoptosis on T24 human bladder cancer cells via multiple pathways.

Bognar Z, Fekete K, Antus C, Hocsak E, Bognar R, Tapodi A, Boronkai A, Farkas N, Gallyas F Jr, Sumegi B, Szanto A.

PLoS One. 2017 Dec 8;12(12):e0189470. doi: 10.1371/journal.pone.0189470. eCollection 2017.

9.

PARP inhibition protects mitochondria and reduces ROS production via PARP-1-ATF4-MKP-1-MAPK retrograde pathway.

Hocsak E, Szabo V, Kalman N, Antus C, Cseh A, Sumegi K, Eros K, Hegedus Z, Gallyas F Jr, Sumegi B, Racz B.

Free Radic Biol Med. 2017 Jul;108:770-784. doi: 10.1016/j.freeradbiomed.2017.04.018. Epub 2017 Apr 27.

10.

Chronic PARP-1 inhibition reduces carotid vessel remodeling and oxidative damage of the dorsal hippocampus in spontaneously hypertensive rats.

Eros K, Magyar K, Deres L, Skazel A, Riba A, Vamos Z, Kalai T, Gallyas F Jr, Sumegi B, Toth K, Halmosi R.

PLoS One. 2017 Mar 24;12(3):e0174401. doi: 10.1371/journal.pone.0174401. eCollection 2017.

11.

BGP-15 Protects against Oxidative Stress- or Lipopolysaccharide-Induced Mitochondrial Destabilization and Reduces Mitochondrial Production of Reactive Oxygen Species.

Sumegi K, Fekete K, Antus C, Debreceni B, Hocsak E, Gallyas F Jr, Sumegi B, Szabo A.

PLoS One. 2017 Jan 3;12(1):e0169372. doi: 10.1371/journal.pone.0169372. eCollection 2017.

12.

Thymic Atrophy and Apoptosis of CD4+CD8+ Thymocytes in the Cuprizone Model of Multiple Sclerosis.

Solti I, Kvell K, Talaber G, Veto S, Acs P, Gallyas F Jr, Illes Z, Fekete K, Zalan P, Szanto A, Bognar Z.

PLoS One. 2015 Jun 8;10(6):e0129217. doi: 10.1371/journal.pone.0129217. eCollection 2015.

13.

Role of mitochondrial network stabilisation by a human small heat shock protein in tumour malignancy.

Turi Z, Hocsak E, Racz B, Szabo A, Balogh A, Sumegi B, Gallyas F Jr.

J Cancer. 2015 Mar 25;6(5):470-6. doi: 10.7150/jca.11494. eCollection 2015.

14.

Cyclophilin D disruption attenuates lipopolysaccharide-induced inflammatory response in primary mouse macrophages.

Priber J, Fonai F, Jakus PB, Racz B, Chinopoulos C, Tretter L, Gallyas F Jr, Sumegi B, Veres B.

Biochem Cell Biol. 2015 Jun;93(3):241-50. doi: 10.1139/bcb-2014-0120. Epub 2015 Jan 23.

PMID:
25728038
15.

Mechanism of the "dark" axonal degeneration in the central nervous system.

Pál J, Gallyas F Sr.

Ideggyogy Sz. 2014 Sep 30;67(9-10):323-30.

PMID:
25518260
16.

Novel mechanisms of sildenafil in pulmonary hypertension involving cytokines/chemokines, MAP kinases and Akt.

Kiss T, Kovacs K, Komocsi A, Tornyos A, Zalan P, Sumegi B, Gallyas F Jr, Kovacs K.

PLoS One. 2014 Aug 18;9(8):e104890. doi: 10.1371/journal.pone.0104890. eCollection 2014.

17.

PARP-inhibitor treatment prevents hypertension induced cardiac remodeling by favorable modulation of heat shock proteins, Akt-1/GSK-3β and several PKC isoforms.

Deres L, Bartha E, Palfi A, Eros K, Riba A, Lantos J, Kalai T, Hideg K, Sumegi B, Gallyas F, Toth K, Halmosi R.

PLoS One. 2014 Jul 11;9(7):e102148. doi: 10.1371/journal.pone.0102148. eCollection 2014.

18.

A quinazoline-derivative compound with PARP inhibitory effect suppresses hypertension-induced vascular alterations in spontaneously hypertensive rats.

Magyar K, Deres L, Eros K, Bruszt K, Seress L, Hamar J, Hideg K, Balogh A, Gallyas F Jr, Sumegi B, Toth K, Halmosi R.

Biochim Biophys Acta. 2014 Jul;1842(7):935-44. doi: 10.1016/j.bbadis.2014.03.008. Epub 2014 Mar 19.

19.

PARP inhibition attenuates acute kidney allograft rejection by suppressing cell death pathways and activating PI-3K-Akt cascade.

Kalmar-Nagy K, Degrell P, Szabo A, Sumegi K, Wittmann I, Gallyas F Jr, Sumegi B.

PLoS One. 2013 Dec 3;8(12):e81928. doi: 10.1371/journal.pone.0081928. eCollection 2013.

20.

Antioxidant and anti-inflammatory effects in RAW264.7 macrophages of malvidin, a major red wine polyphenol.

Bognar E, Sarszegi Z, Szabo A, Debreceni B, Kalman N, Tucsek Z, Sumegi B, Gallyas F Jr.

PLoS One. 2013 Jun 5;8(6):e65355. doi: 10.1371/journal.pone.0065355. Print 2013.

21.

TRAF6 is functional in inhibition of TLR4-mediated NF-κB activation by resveratrol.

Jakus PB, Kalman N, Antus C, Radnai B, Tucsek Z, Gallyas F Jr, Sumegi B, Veres B.

J Nutr Biochem. 2013 May;24(5):819-23. doi: 10.1016/j.jnutbio.2012.04.017. Epub 2012 Aug 24.

PMID:
22925919
22.

Hydroximic acid derivatives: pleiotropic HSP co-inducers restoring homeostasis and robustness.

Crul T, Toth N, Piotto S, Literati-Nagy P, Tory K, Haldimann P, Kalmar B, Greensmith L, Torok Z, Balogh G, Gombos I, Campana F, Concilio S, Gallyas F, Nagy G, Berente Z, Gungor B, Peter M, Glatz A, Hunya A, Literati-Nagy Z, Vigh L Jr, Hoogstra-Berends F, Heeres A, Kuipers I, Loen L, Seerden JP, Zhang D, Meijering RA, Henning RH, Brundel BJ, Kampinga HH, Koranyi L, Szilvassy Z, Mandl J, Sumegi B, Febbraio MA, Horvath I, Hooper PL, Vigh L.

Curr Pharm Des. 2013;19(3):309-46. Review.

PMID:
22920902
23.

[Report from the 2011 scientific meeting of the Környey Society. Part 1].

Pálffy G, Poór G, Környey E, Illés Z, Kopa J, Kovács N, Barzo P, Bereczki D, Bodosi M, Csiba L, Dóczi T, Fekete S, Gallyas F, Hegedűs K, Komoly S, Szirmai I, Vécsei L.

Ideggyogy Sz. 2011 Nov 30;64(11-12):418-26. Hungarian. No abstract available.

PMID:
22611621
24.

Protective effect of the poly(ADP-ribose) polymerase inhibitor PJ34 on mitochondrial depolarization-mediated cell death in hepatocellular carcinoma cells involves attenuation of c-Jun N-terminal kinase-2 and protein kinase B/Akt activation.

Radnai B, Antus C, Racz B, Engelmann P, Priber JK, Tucsek Z, Veres B, Turi Z, Lorand T, Sumegi B, Gallyas F Jr.

Mol Cancer. 2012 May 14;11:34. doi: 10.1186/1476-4598-11-34.

25.

Involvement of redox-signalling in endogenous hydrogen sulfide production.

Gallyas F.

Br J Pharmacol. 2012 Aug;166(8):2228-30. doi: 10.1111/j.1476-5381.2012.01976.x.

26.

BGP-15, a PARP-inhibitor, prevents imatinib-induced cardiotoxicity by activating Akt and suppressing JNK and p38 MAP kinases.

Sarszegi Z, Bognar E, Gaszner B, Kónyi A, Gallyas F Jr, Sumegi B, Berente Z.

Mol Cell Biochem. 2012 Jun;365(1-2):129-37. doi: 10.1007/s11010-012-1252-8. Epub 2012 Feb 14.

PMID:
22350755
27.

High-throughput screening of saliva for early detection of oral cancer: a pilot study.

Szanto I, Mark L, Bona A, Maasz G, Sandor B, Gelencser G, Turi Z, Gallyas F Jr.

Technol Cancer Res Treat. 2012 Apr;11(2):181-8.

PMID:
22335413
28.

Induction of mitochondrial destabilization and necrotic cell death by apolar mitochondria-directed SOD mimetics.

Szabo A, Balog M, Mark L, Montsko G, Turi Z, Gallyas F Jr, Sumegi B, Kalai T, Hideg K, Kovacs K.

Mitochondrion. 2011 May;11(3):476-87. doi: 10.1016/j.mito.2011.01.006. Epub 2011 Feb 1.

PMID:
21292036
29.
30.

Regulation of MKP-1 expression and MAPK activation by PARP-1 in oxidative stress: a new mechanism for the cytoplasmic effect of PARP-1 activation.

Racz B, Hanto K, Tapodi A, Solti I, Kalman N, Jakus P, Kovacs K, Debreceni B, Gallyas F Jr, Sumegi B.

Free Radic Biol Med. 2010 Dec 15;49(12):1978-88. doi: 10.1016/j.freeradbiomed.2010.09.026. Epub 2010 Oct 16.

PMID:
20920579
31.

Suppressing LPS-induced early signal transduction in macrophages by a polyphenol degradation product: a critical role of MKP-1.

Tucsek Z, Radnai B, Racz B, Debreceni B, Priber JK, Dolowschiak T, Palkovics T, Gallyas F Jr, Sumegi B, Veres B.

J Leukoc Biol. 2011 Jan;89(1):105-11. doi: 10.1189/jlb.0610355. Epub 2010 Sep 30.

PMID:
20884647
32.

TIP47 confers resistance to taxol-induced cell death by preventing the nuclear translocation of AIF and Endonuclease G.

Hocsak E, Racz B, Szabo A, Pozsgai E, Szigeti A, Szigeti E, Gallyas F Jr, Sumegi B, Javor S, Bellyei S.

Eur J Cell Biol. 2010 Nov;89(11):853-61. doi: 10.1016/j.ejcb.2010.06.010. Epub 2010 Aug 12.

PMID:
20708296
33.

Pituitary adenylate cyclase activating polypeptide in the retina: focus on the retinoprotective effects.

Atlasz T, Szabadfi K, Kiss P, Racz B, Gallyas F, Tamas A, Gaal V, Marton Z, Gabriel R, Reglodi D.

Ann N Y Acad Sci. 2010 Jul;1200:128-39. doi: 10.1111/j.1749-6632.2010.05512.x. Review.

PMID:
20633141
34.

TIP47 protects mitochondrial membrane integrity and inhibits oxidative-stress-induced cell death.

Hocsak E, Racz B, Szabo A, Mester L, Rapolti E, Pozsgai E, Javor S, Bellyei S, Gallyas F Jr, Sumegi B, Szigeti A.

FEBS Lett. 2010 Jul 2;584(13):2953-60.

35.

Effects of PACAP on mitochondrial apoptotic pathways and cytokine expression in rats subjected to renal ischemia/reperfusion.

Horvath G, Racz B, Reglodi D, Kovacs K, Kiss P, Gallyas F Jr, Bognar Z, Szabo A, Magyarlaki T, Laszlo E, Lubics A, Tamas A, Toth G, Szakaly P.

J Mol Neurosci. 2010 Nov;42(3):411-8. doi: 10.1007/s12031-010-9342-0. Epub 2010 Mar 16.

PMID:
20229361
36.

Inhibiting poly(ADP-ribose) polymerase: a potential therapy against oligodendrocyte death.

Veto S, Acs P, Bauer J, Lassmann H, Berente Z, Setalo G Jr, Borgulya G, Sumegi B, Komoly S, Gallyas F Jr, Illes Z.

Brain. 2010 Mar;133(Pt 3):822-34. doi: 10.1093/brain/awp337. Epub 2010 Feb 15.

37.

PACAP ameliorates oxidative stress in the chicken inner ear: an in vitro study.

Racz B, Horvath G, Reglodi D, Gasz B, Kiss P, Gallyas F Jr, Sumegi B, Toth G, Nemeth A, Lubics A, Tamas A.

Regul Pept. 2010 Feb 25;160(1-3):91-8. doi: 10.1016/j.regpep.2009.12.003. Epub 2009 Dec 4.

PMID:
19969027
38.

Facilitation of mitochondrial outer and inner membrane permeabilization and cell death in oxidative stress by a novel Bcl-2 homology 3 domain protein.

Szigeti A, Hocsak E, Rapolti E, Racz B, Boronkai A, Pozsgai E, Debreceni B, Bognar Z, Bellyei S, Sumegi B, Gallyas F Jr.

J Biol Chem. 2010 Jan 15;285(3):2140-51. doi: 10.1074/jbc.M109.015222. Epub 2009 Nov 9.

39.

Potentiation of paclitaxel-induced apoptosis by galectin-13 overexpression via activation of Ask-1-p38-MAP kinase and JNK/SAPK pathways and suppression of Akt and ERK1/2 activation in U-937 human macrophage cells.

Boronkai A, Bellyei S, Szigeti A, Pozsgai E, Bognar Z, Sumegi B, Gallyas F Jr.

Eur J Cell Biol. 2009 Dec;88(12):753-63. doi: 10.1016/j.ejcb.2009.07.005. Epub 2009 Aug 31.

PMID:
19717209
40.

Protection against chronic hypoperfusion-induced retinal neurodegeneration by PARP inhibition via activation of PI-3-kinase Akt pathway and suppression of JNK and p38 MAP kinases.

Mester L, Szabo A, Atlasz T, Szabadfi K, Reglodi D, Kiss P, Racz B, Tamas A, Gallyas F Jr, Sumegi B, Hocsak E, Gabriel R, Kovacs K.

Neurotox Res. 2009 Jul;16(1):68-76. doi: 10.1007/s12640-009-9049-6. Epub 2009 Apr 9.

PMID:
19526300
41.

Effects of PACAP and preconditioning against ischemia/reperfusion-induced cardiomyocyte apoptosis in vitro.

Roth E, Wéber G, Kiss P, Horváth G, Tóth G, Gasz B, Ferencz A, Gallyas F Jr, Reglodi D, Rácz B.

Ann N Y Acad Sci. 2009 Apr;1163:512-6. doi: 10.1111/j.1749-6632.2008.03635.x.

PMID:
19456402
42.

PARP-1 inhibition-induced activation of PI-3-kinase-Akt pathway promotes resistance to taxol.

Szanto A, Hellebrand EE, Bognar Z, Tucsek Z, Szabo A, Gallyas F Jr, Sumegi B, Varbiro G.

Biochem Pharmacol. 2009 Apr 15;77(8):1348-57. doi: 10.1016/j.bcp.2009.01.008. Epub 2009 Jan 24.

PMID:
19426673
43.

Critical role of bad phosphorylation by Akt in cytostatic resistance of human bladder cancer cells.

Szanto A, Bognar Z, Szigeti A, Szabo A, Farkas L, Gallyas F Jr.

Anticancer Res. 2009 Jan;29(1):159-64.

44.

Supravital microwave experiments support that the formation of "dark" neurons is propelled by phase transition in an intracellular gel system.

Gallyas F, Pál J, Bukovics P.

Brain Res. 2009 May 13;1270:152-6. doi: 10.1016/j.brainres.2009.03.020. Epub 2009 Mar 24.

PMID:
19324025
45.

Ferulaldehyde, a water-soluble degradation product of polyphenols, inhibits the lipopolysaccharide-induced inflammatory response in mice.

Radnai B, Tucsek Z, Bognar Z, Antus C, Mark L, Berente Z, Gallyas F Jr, Sumegi B, Veres B.

J Nutr. 2009 Feb;139(2):291-7. doi: 10.3945/jn.108.097386. Epub 2008 Dec 23.

PMID:
19106314
46.
47.

Prevalent role of Akt and ERK activation in cardioprotective effect of Ca(2+) channel- and beta-adrenergic receptor blockers.

Kovacs K, Hanto K, Bognar Z, Tapodi A, Bognar E, Kiss GN, Szabo A, Rappai G, Kiss T, Sumegi B, Gallyas F Jr.

Mol Cell Biochem. 2009 Jan;321(1-2):155-64. doi: 10.1007/s11010-008-9929-8. Epub 2008 Oct 31.

PMID:
18975057
48.

The mode of death of epilepsy-induced "dark" neurons is neither necrosis nor apoptosis: an electron-microscopic study.

Gallyas F, Kiglics V, Baracskay P, Juhász G, Czurkó A.

Brain Res. 2008 Nov 6;1239:207-15. doi: 10.1016/j.brainres.2008.08.069. Epub 2008 Sep 4.

PMID:
18801347
49.

Aldehyde fixation is not necessary for the formation of "dark" neurons.

Bukovics P, Pál J, Gallyas F.

Acta Neuropathol. 2008 Oct;116(4):463-4. doi: 10.1007/s00401-008-0424-9. Epub 2008 Aug 12. No abstract available.

PMID:
18696090
50.

Alcohol-free red wine inhibits isoproterenol-induced cardiac remodeling in rats by the regulation of Akt1 and protein kinase C alpha/beta II.

Palfi A, Bartha E, Copf L, Mark L, Gallyas F Jr, Veres B, Kalman E, Pajor L, Toth K, Ohmacht R, Sumegi B.

J Nutr Biochem. 2009 Jun;20(6):418-25. doi: 10.1016/j.jnutbio.2008.04.009. Epub 2008 Jul 24.

PMID:
18656339

Supplemental Content

Loading ...
Support Center